BCMA CAR-T cells in multiple myeloma-ready for take-off? (Record no. 27976)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02159nam a22003497a 4500 |
| 001 - CONTROL NUMBER | |
| control field | 20240607164401.0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | 20240607164401.0 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240607165345.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240607b |||||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | ddc |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Fuller form of name | Lukas Scheller |
| 245 ## - TITLE STATEMENT | |
| Title | BCMA CAR-T cells in multiple myeloma-ready for take-off? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mwanza, Tanzania : |
| Name of publisher, distributor, etc. | Catholic University of Health and Allied Sciences [CUHAS-Bugando] : |
| Date of publication, distribution, etc. | 2023 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | Pages 143-157 |
| Extent | Includes References |
| 490 ## - SERIES STATEMENT | |
| Volume/sequential designation | Leukemia & Lymphoma Volume 65, 2024 - Issue 2 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Abstract :<br/><br/>Although the approval of new drugs has improved the clinical outcome of multiple myeloma (MM), it was widely regarded as incurable over the past decades. However, recent advancements in groundbreaking immunotherapies, such as chimeric antigen receptor T cells (CAR-T), have yielded remarkable results in heavily pretreated relapse/refractory patients, instilling hope for a potential cure. CAR-T are genetically modified cells armed with a novel receptor to specifically recognize and kill tumor cells. Among the potential targets for MM, the B-cell maturation antigen (BCMA) stands out since it is highly and almost exclusively expressed on plasma cells. Here, we review the currently approved BCMA-directed CAR-T products and ongoing clinical trials in MM. Furthermore, we explore innovative approaches to enhance BCMA-directed CAR-T and overcome potential reasons for treatment failure. Additionally, we explore the side effects associated with these novel therapies and shed light on accessibility of CAR-T therapy around the world. |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | BCMA |
| General subdivision | multiple myeloma |
| General subdivision | clinical trials |
| General subdivision | CAR-T |
| General subdivision | chimeric antigen receptor T cell |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Fuller form of name | Erius Tebuka |
| Fuller form of name | Peter Fabian Rambau |
| Fuller form of name | Hermann Einsele |
| Fuller form of name | Michael Hudecek |
| Fuller form of name | Sabrina Rebecca Prommersberger |
| Fuller form of name | Sophia Danhof |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1080/10428194.2023.2276676 ">https://doi.org/10.1080/10428194.2023.2276676 </a> |
| Link text | https://doi.org/10.1080/10428194.2023.2276676 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | RESEARCH ARTICLES |
| Suppress in OPAC | |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Date acquired | Total checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 06/07/2024 | 20240607164401.0 | 06/07/2024 | 06/07/2024 | RESEARCH ARTICLES |